Tumor treating fields as novel combination partner in the multimodal treatment of head and neck cancer

被引：5

作者：

Regnery, Sebastian ^{[1
]}

Franke, Henrik ^{[1
,2
]}

Held, Thomas ^{[1
,2
]}

Trinh, Thuy ^{[1
,2
]}

Naveh, Ariel ^{[3
]}

Abraham, Yissachar ^{[3
]}

Hoerner-Rieber, Juliane ^{[1
,2
]}

Hess, Jochen ^{[4
,5
]}

Huber, Peter E. ^{[1
,2
]}

Debus, Juergen ^{[1
,2
]}

Perez, Ramon Lopez ^{[2
]}

Adeberg, Sebastian ^{[1
,2
,6
]}

机构：

[1] Heidelberg Univ Hosp, Dept Radiat Oncol, Heidelberg, Germany

[2] German Canc Res Ctr, Clin Cooperat Unit Mol & Radiat Oncol, Heidelberg, Germany

[3] Novocure Ltd, Haifa, Israel

[4] Heidelberg Univ Hosp, Dept Otorhinolaryngol, Sect Expt & Translat Head & neck Oncol, Heidelberg, Germany

[5] German Canc Res Ctr, Res Grp Mol Mech Head & Neck Tumors, Heidelberg, Germany

[6] Heidelberg Univ Hosp, Dept Radiat Oncol, Im Neuenheimer Feld 400, D-69120 Heidelberg, Germany

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2023年 / 45卷 / 04期

关键词：

chemoradiotherapy; head and neck cancer; radiotherapy; squamous cell carcinoma of head and neck; tumor treating fields; CELLS IN-VITRO; CHEMOTHERAPY; TTFIELDS; TRIALS; PROLIFERATION; DISRUPTION; VIVO;

D O I：

10.1002/hed.27298

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

BackgroundWe aimed to demonstrate the effects of tumor treating fields (TTFields) in head and neck squamous cell carcinoma (HNSCC) cells when combined with radiotherapy (RT) and chemotherapy. MethodsTwo human HNSCC cell lines (Cal27, FaDu) received five different treatments: TTFields, RT +/- TTFields and RT + simultaneous cisplatin +/- TTFields. Effects were quantified using clonogenic assays and flow cytometric analyses of DAPI, caspase-3 activation and gamma H2AX foci. ResultsTreatment with RT + TTFields decreased the clonogenic survival as strong as treatment with RT + simultaneous cisplatin. The triple combination of RT + simultaneous cisplatin + TTFields even further decreased the clonogenic survival. Accordingly, combination of TTFields with RT or RT + simultaneous cisplatin increased cellular apoptosis and DNA double-strand breaks. ConclusionTTFields therapy seems a promising combination partner in the multimodal treatment of locally advanced HNSCC. It could be used to intensify chemoradiotherapy or as alternative to chemotherapy.

引用

页码：838 / 848

页数：11

共 37 条

[1]

Adeberg S., 2021, DEGRO 2021, P1

[2] Defining risk levels in locally advanced head and neck cancers:: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501) [J].

Bernier, J ;

Cooper, JS ;

Pajak, TF ;

van Glabbeke, M ;

Bourhis, J ;

Forastiere, A ;

Ozsahin, EM ;

Jacobs, JR ;

Jassem, J ;

Ang, KK ;

Lefèbvre, JL .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2005, 27 (10) :843-850

[3] In Vivo Safety of Tumor Treating Fields (TTFields) Applied to the Torso [J].

Blatt, Roni ;

Davidi, Shiri ;

Munster, Mijal ;

Shteingauz, Anna ;

Cahal, Shay ;

Zeidan, Adel ;

Marciano, Tal ;

Bomzon, Zeev ;

Haber, Adi ;

Giladi, Moshe ;

Weinberg, Uri ;

Kinzel, Adrian ;

Palti, Yoram .

FRONTIERS IN ONCOLOGY, 2021, 11

[4]

CARPENTIER Y, 1993, ANTICANCER RES, V13, P2177

[5] Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial [J].

Ceresoli, Giovanni L. ;

Aerts, Joachim G. ;

Dziadziuszko, Rafal ;

Ramlau, Rodryg ;

Cedres, Susana ;

van Meerbeeck, Jan P. ;

Mencoboni, Manlio ;

Planchard, David ;

Chella, Antonio ;

Crino, Lucio ;

Krzakowski, Maciej ;

Russel, Jorn ;

Maconi, Antonio ;

Gianoncelli, Letizia ;

Grosso, Federica .

LANCET ONCOLOGY, 2019, 20 (12) :1702-1709

[6] Head and Neck Cancer [J].

Chow, Laura Q. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01) :60-72

[7] Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study [J].

Cohen, Ezra E. W. ;

Soulieres, Denis ;

Le Tourneau, Christophe ;

Dinis, Jose ;

Licitra, Lisa ;

Ahn, Myung-Ju ;

Soria, Ainara ;

Machiels, Jean-Pascal ;

Mach, Nicolas ;

Mehra, Ranee ;

Burtness, Barbara ;

Zhang, Pingye ;

Cheng, Jonathan ;

Swaby, Ramona F. ;

Harrington, Kevin J. .

LANCET, 2019, 393 (10167) :156-167

[8] The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers [J].

Dyba, Tadeusz ;

Randi, Giorgia ;

Bray, Freddie ;

Martos, Carmen ;

Giusti, Francesco ;

Nicholson, Nicholas ;

Gavin, Anna ;

Flego, Manuela ;

Neamtiu, Luciana ;

Dimitrova, Nadya ;

Carvalho, Raquel Negrao ;

Ferlay, Jacques ;

Bettio, Manola .

EUROPEAN JOURNAL OF CANCER, 2021, 157 :308-347

[9]

Franke H., 2022, TUMOR TREATING FIELD

[10] Clonogenic assay of cells in vitro [J].

Franken, Nicolaas A. P. ;

Rodermond, Hans M. ;

Stap, Jan ;

Haveman, Jaap ;

van Bree, Chris .

NATURE PROTOCOLS, 2006, 1 (05) :2315-2319

← 1 2 3 4 →